United Therapeutics reported unexpected positive results from a Phase 3 trial of nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis, a condition known for its limited treatment options. Tyvaso improved forced vital capacity at one year and demonstrated consistent benefits across subgroups, including those on standard therapies. The drug was well tolerated, and safety data aligned with previous studies. The findings prompted a significant stock price surge and set the stage for a supplemental NDA submission, opening access to a potential $4 billion-plus market.